Laurus Labs Ltd., incorporated in the year 2005, is a Mid Cap company (having a market cap of Rs 16288.89 Crore) operating in Pharmaceuticals sector.
By ETMarkets.com | Updated:
BCCL - Non Copyright
Promoters held 32.1 per cent stake in the company as of Sept 30, 2020, while FIIs held 20.7 per cent, DIIs 6.3 per cent and public and others 40.8 per cent.
Motilal Oswal has given a buy rating to Laurus Labs with a target price of Rs 410. The share price moved up by 3.63 per cent from its previous close of Rs 292.25. The stock’s last traded price is Rs 302.85.
Laurus Labs Ltd., incorporated in the year 2005, is a Mid Cap company (having a market cap of Rs 16288.89 Crore) operating in Pharmaceuticals sector.
Financials For the quarter ended 30-09-2020, the company reported a Consolidated sales of Rs 1138.84 Crore, up 16.89 % from last quarter Sales of Rs 974.32 Crore and up 59.85 % from last year same quarter Sales of Rs 712.42 Crore Company reported net profit after tax of Rs 242.27 Crore in latest quarter.
Investment Rationale The brokerage remains positive on LAURUS on the back of: a) superior execution in the ARV segment, b) strong chemistry skillset driving the CDMO business and the addition of a new leg to the CDMO business, which vastly expands its total addressable market, c) the addition of new molecules in the other API segment, and d) cost efficiency aiding profitability.
Promoter/FII Holdings Promoters held 32.1 per cent stake in the company as of Sept 30, 2020, while FIIs held 20.7 per cent, DIIs 6.3 per cent and public and others 40.8 per cent.
